CD1a and antitumour immune response

Rocca, Giampiero La; Anzalone, Rita; Bucchieri, Fabio; Farina, Felicia; Cappello, Francesco; Zummo, Giovanni

doi:10.1016/j.imlet.2004.05.006

Cited by 29 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is similar to our recent findings regarding metaplasiaadenocarcinoma progression in Barrett's oesophagus, 5,6 which led us to hypothesize a possible co-stimulatory effect of this molecule on the functional immune response. 7 The present data suggest that evaluation of CD1a expression at the LN level by means of molecular diagnostic analyses might help to address the presence of occult micrometastases. In addition, these results support the hypothesis that a greater number of CD1a+ mononuclear cells in the tumour node microenvironment may lead to the initiation of a functional host response to the malignancy.…”

Section: Discussionmentioning

confidence: 69%

“…The interaction between DCs, CD1a-immunoreactive epithelial cells and T cells might potentiate the antitumour defence, at least in BM. 7 In the present study, the presence of CD1a at both primary tumour and LN level was investigated in a homogeneous group of invasive ductal carcinomas (IDC) of the breast and CD1a immunoreactivity was correlated with clinical and pathological data.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD1a down‐regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

et al. 2007

View full text Add to dashboard Cite

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome Aims: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumourderived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. Methods and results: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P = 0.0025) and progesterone (P = 0.0226) receptor (PR) status, as well as CD4+ and CD8+ T-lymphocyte infiltration. Conclusions: This is the first report to show a link between CD1a+ mononuclear cells in breast cancer and in paired LN metastases. The positive and significant correlations between the number of CD1a+ cells and positivity of the primary tumour for ER and PR suggest a possible role for CD1a as a prognostic marker for breast cancer, raising the possibility that hormone receptor-positive breast cancer patients may have a better prognosis in the presence of greater dendritic cell infiltration.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

CD1a down‐regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In particular, we postulated a diagnostic role of this marker and supposed that it may also be useful to predict prognosis. Moreover, we already hypothesised a proimmunitary role of CD1a expression by epithelial cells (La Rocca et al, 2004), in accordance to Coventry and Heinzel (2004).…”

Section: Discussionmentioning

confidence: 75%

“…The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003).…”

mentioning

confidence: 89%

“…CD1a is a surface glycoprotein of 43 -49 kDa that has been shown to be expressed by dendritic cells (DCs), cortical thymocytes and Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;Krenacs et al, 1993;Gregory et al, 2000). Moreover, the research of CD1a is commonly used to differentiate various cutaneous T-cell lymphomas from B-cell lymphomasand pseudolymphomas (Arai et al, 1999;Schmuth et al, 2001).The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003).…”

mentioning

confidence: 99%

See 1 more Smart Citation

CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer

et al. 2005

View full text Add to dashboard Cite

As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The aim of the present work was to investigate the expression of CD1a in a series of Barrett's metaplasia (BM), gastric type (GTBM), with and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome. Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca; nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology. CD1a is a surface glycoprotein of 43 -49 kDa that has been shown to be expressed by dendritic cells (DCs), cortical thymocytes and Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;Krenacs et al, 1993;Gregory et al, 2000). Moreover, the research of CD1a is commonly used to differentiate various cutaneous T-cell lymphomas from B-cell lymphomasand pseudolymphomas (Arai et al, 1999;Schmuth et al, 2001).The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003). In particular, we postulated that this marker may be useful in diagnosing Barrett's metaplasia (BM) and we hypothesised that its expression could predict a favourable outcome of this disease (Cappello, 2004).Indeed, BM may evolve towards dysplasia (Dy) or carcinoma (Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;Moreto, 2003). Nevertheless, to date, we do not have any marker that could help to predict BM evolution.The aim of the present work was to detect CD1a expression in a large series of BM, Dy and Ca at the time of diagnosis and at follow-up. We would verify the diagnostic role of CD1a for BM and confirm our hypothesis concerning its prognostic role. MATERIALS AND METHODS Sample collectionWe selected retrospectively from our files, 222 cases as follows: 166 specimens were BM of gastric type (GTBM) that underwent follow up; moreover, we selected 37 specimens of Dy and 19 of Ca that did not undergo follow-up. Finally, as control group, we selected 10 specimens from normal gastric mucosa. Sample collection was performed according to ethical standards. In addition, we collected, from the 166 cases of GTBM, the specimens that underwent follow-up, commonly between 12 and 36 months from first diagnosis; in 134 cases, the diagnosis of BM was confirmed (FU-GTBM), while in 23 cases, GTBM evolved towards dysplasia (FU-Dy) and in nine cases towards carcinoma (FU-Ca). Imm...

show abstract

High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma

Park

Lee

Yoon

2012

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

CD1a and antitumour immune response

Cited by 29 publications

References 28 publications

CD1a down‐regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

CD1a down‐regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer

High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma

Contact Info

Product

Resources

About